SCHEMBL4975309

SCHEMBL4975309

C#Cc1cccc2ncn(CC(=O)Nc3cc(OC)cc(OC)c3)c12

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.46
LMNA P02545 2/20 0.45
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
HSD17B10 Q99714 1/20 0.43
MAPT P10636 5/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
HTT P42858 1/20 0.43
TP53 P04637 1/20 0.43
ACHE P22303 1/20 0.42
BACE1 P56817 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3038752 0.91 POLB (0.46) POLBLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL4974551 0.89 POLB (0.45) POLBLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL3041004 0.86 MAPT (0.48) POLBLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL4975792 0.86 POLB (0.54) POLBLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL3045782 0.85 SMN1; SMN2 (0.51) POLBLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL3042993 0.84 POLB (0.48) POLBLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL3035237 0.84 SMN1; SMN2 (0.52) POLBLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL4977062 0.84 POLB (0.46) POLBLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL3043480 0.84 AR (0.49) POLBLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL3042146 0.84 CSF1R (0.51) POLBALDH1A1KDM4ESMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015222-A1 New Heterocyclic Amides ASTRAZENECA AB (SE) 2008-01-17 US claimed
EP-1797067-A1 NEW HETEROCYCLIC AMIDES AstraZeneca AB (SE) 2007-06-20 EP claimed
WO-2006033620-A1 NEW HETEROCYCLIC AMIDES ASTRAZENECA AB (SE) 2006-03-30 WO claimed
US-20080015222-A1 New Heterocyclic Amides ASTRAZENECA AB (SE) 2008-01-17 US disclosed
EP-1797067-A1 NEW HETEROCYCLIC AMIDES AstraZeneca AB (SE) 2007-06-20 EP disclosed
WO-2006033620-A1 NEW HETEROCYCLIC AMIDES ASTRAZENECA AB (SE) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015222-A1 New Heterocyclic Amides AADAC, AVPR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 POLB 2972/4885LMNA 2368/4885ALDH1A1 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.